Anakinra

Chemical formula: C₂₀H₂₃N₅O₇S₂ Molecular mass: 509.6 g/mol

Therapeutic indications

Anakinra is indicated for:

Rheumatoid arthritis (RA)

Population group: only adults (18 years old or older)

Anakinra is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100 mg once daily

Cryopyrin-Associated Periodic Syndromes (CAPS)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Anakinra is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of CAPS, including:

Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)
Muckle-Wells Syndrome (MWS)
Familial Cold Autoinflammatory Syndrome (FCAS)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1-2 mg/kg/day as starting dose and thereafter 1-8 mg/kg/day

Still's disease

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Anakinra is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighing ≥50 kg 100 mg/day and for patients weighing <50 kg 1-2 mg/kg/day

For patients weighing ≥50 kg 100 mg/day and for patients weighing <50 kg 1-2 mg/kg/day

1-2 mg/kg/day

Familial Mediterranean Fever (FMF)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Anakinra is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Familial Mediterranean Fever (FMF). Anakinra should be given in combination with colchicine, if appropriate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighing ≥50 kg 100 mg/day and for patients weighing <50 kg 1-2 mg/kg/day

COVID-19 with suPAR ≥6 ng/ml

Population group: only adults (18 years old or older)

Anakinra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥6 ng/ml.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100 mg once daily for 10 days

Contraindications

Anakinra is contraindicated in the following cases:

Neutropenia

Neutropenia

Lactation

Lactation

Active infections

Infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈